Roche Holding AG (Roche Holding AG) Short Percentage of Float

View and export this data going back to . Start your Free Trial

What is Roche Holding AG Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Roche Holding AG's Short Percentage of Float

For the Drug Manufacturers - General subindustry, Roche Holding AG's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Short Percentage of Float falls into.

Roche Holding AG (Roche Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHVF) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

RHHBY:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.